Advertisement

Does Adding Daratumumab to Lenalidomide/Dexamethasone Improve Outcomes in Previously Treated Multiple Myeloma?

Advertisement

Key Points

  • The addition of daratumumab to lenalidomide/dexamethasone was associated with a significant improvement in progression-free survival in patients with relapsed/refractory multiple myeloma.
  • Complete response or better was observed in 43.1% vs 19.2% of patients.

The addition of the CD38-targeted antibody daratumumab (Darzalex) to lenalidomide (Revlimid)/dexamethasone improved progression-free survival in patients with previously treated multiple myeloma, according to the results of the phase III POLLUX trial reported by Dimopoulos et al in The New England Journal of Medicine.

Study Details

In the open-label trial, 569 patients from 135 sites in 18 countries across North America, Europe, and the Asia-Pacific region who had relapsed/refractory disease and had received at least 1 previous line of therapy were randomized between June 2014 and July 2015 to receive daratumumab plus lenalidomide/dexamethasone (n = 286) vs lenalidomide/dexamethasone alone (n = 283).

Daratumumab was given via infusion at 16 mg/kg weekly for 8 weeks, every 2 weeks for 16 weeks, and every 4 weeks thereafter. Lenalidomide was given at 25 mg daily orally (10 mg daily for creatinine clearance of 30–60 mL/min) of each 4-week cycle and dexamethasone at 40 mg weekly; the dexamethasone dose was split in the daratumumab group as 20 mg preinfusion prophylaxis and 20 mg the following day. The primary endpoint was progression-free survival.

Overall, patients had a median age of 65 years (range = 34–89 years), median time from initial diagnosis was 3.6 years, median number of previous lines of therapy was 1 (range = 1–11) with 19% receiving at least 3 lines, and 27% had disease refractory to the last line of therapy. Previous therapy included proteasome inhibitors in 86% of patients, immunomodulatory drugs in 55% (including lenalidomide in 18%), and both in 44%; 63% had received autologous stem cell transplant. For the daratumumab and control groups: 72% and 66% of patients were white and 19% and 16% were Asian; the International Staging System (ISS) stage was I in 48% and 50% and II in 32% and 30%; and 15% and 17% had high-risk cytogenetics, respectively.

Improved Progression-Free Survival

At a protocol-specified interim analysis at a median follow-up of 13.5 months, disease progression or death had occurred in 18.5% of the daratumumab group vs 41.0% of the control group. The hazard ratio (HR) for disease progression or death was 0.37 (95% confidence interval [CI] = 0.27–0.52, P < .001), crossing the prespecified stopping boundary. Median progression-free survival was not reached (95% CI = could not be estimated) vs 18.4 months (95% CI = 13.9 months to could not be estimated). The Kaplan-Meier rate of progression-free survival at 12 months was 83.2% (95% CI = 78.3%–87.2%) vs 60.1% (95% CI = 54.0%–65.7%).

Hazard ratios favored daratumumab in all subgroups examined, including irrespective of the number of previous lines of therapy, whether or not patients had received previous lenalidomide, whether or not patients were refractory to previous proteasome inhibitor treatment, and in patients aged ≥ 65 years.

Response Rates

Overall response rates were 92.9% vs 76.4% (P < .001), with complete response or better observed in 43.1% vs 19.2% (P < .001). Complete response appeared to require several months of continuous therapy. Median duration of response was not reached vs 17.4 months. Progression-free survival at 12 months was 87.8% vs 73.6% among patients with partial response or better and 91.7% vs 85.8% among those with very good partial response or better. Responses below the threshold for minimal residual disease (1 tumor cell/105 white cells) were observed in 22.4% vs 4.6% (P < .001); responses below this threshold were associated with improved outcomes.

At the interim analysis, 30 patients in the daratumumab group had died, as had 45 patients in the control group. The Kaplan-Meier rate of overall survival at 12 months was 92.1% vs 86.8%; follow-up for long-term survival is ongoing.

Adverse Events

The most common adverse events of grade 3 or 4 in the daratumumab group were neutropenia (51.9% vs 37.0%), thrombocytopenia (12.7% vs 13.5%), and anemia (12.4% vs 19.6%). Adverse events of any grade occurring at a frequency ≥ 10% higher in the daratumumab group were neutropenia (59.4% vs 43.1%), diarrhea (42.8% vs 24.6%), upper respiratory tract infection (31.8% vs 20.6%), and cough (29.0% vs 12.5%). Deep-vein thrombosis was reported in 1.8% vs 3.9%. Grade 3 or 4 infection occurred in 28.3% vs 22.8%, with the most common being pneumonia (7.8% vs 8.2%). Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients (5.3% grade 3).

The investigators concluded: “The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy.”

The study was funded by Janssen Research and Development.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement